These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 9676804)

  • 1. Fatal alveolar hemorrhage and Abciximab (ReoPro) therapy for acute myocardial infarction.
    Khanlou H; Tsiodras S; Eiger G; Abousy K; Goldberg S; Nakhjavan F; Yazdanfar S
    Cathet Cardiovasc Diagn; 1998 Jul; 44(3):313-6. PubMed ID: 9676804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alveolar hemorrhage as a complication of treatment with abciximab.
    Kalra S; Bell MR; Rihal CS
    Chest; 2001 Jul; 120(1):126-31. PubMed ID: 11451827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators.
    Brener SJ; Barr LA; Burchenal JE; Katz S; George BS; Jones AA; Cohen ED; Gainey PC; White HJ; Cheek HB; Moses JW; Moliterno DJ; Effron MB; Topol EJ
    Circulation; 1998 Aug; 98(8):734-41. PubMed ID: 9727542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abciximab and fatal pulmonary hemorrhage.
    Usman MH; Shah MA; ul-Islam T; Adenwalla HN; Rahman F; Baqir M; Altaf M; Venkataraman R; Cherayil M; Berger S
    Heart Lung; 2006; 35(6):423-6. PubMed ID: 17137944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergy between intracoronary stenting and abciximab in improving angiographic and clinical outcomes of primary angioplasty in acute myocardial infarction.
    Giri S; Mitchel JF; Hirst JA; McKay RG; Azar RR; Mennett R; Waters DD; Kiernan FJ
    Am J Cardiol; 2000 Aug; 86(3):269-74. PubMed ID: 10922431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence of bleeding complications associated with abciximab use in conjunction with thrombolytic therapy in patients requiring percutaneous transluminal coronary angioplasty.
    Sundlof DW; Rerkpattanapitat P; Wongpraparut N; Pathi P; Kotler MN; Jacobs LE; Ledley GS; Yazdanfar S
    Am J Cardiol; 1999 Jun; 83(11):1569-71, A7. PubMed ID: 10363875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fatal cerebral hemorrhage and severe thrombocytopenia during abciximab treatment.
    Vahdat B; Canavy I; Fourcade L; Garcia E; Quilici J; Bonnet JL; Bory M
    Catheter Cardiovasc Interv; 2000 Feb; 49(2):177-80. PubMed ID: 10642768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction.
    Stone GW; Grines CL; Cox DA; Garcia E; Tcheng JE; Griffin JJ; Guagliumi G; Stuckey T; Turco M; Carroll JD; Rutherford BD; Lansky AJ;
    N Engl J Med; 2002 Mar; 346(13):957-66. PubMed ID: 11919304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Results of primary percutaneous transluminal coronary angioplasty plus abciximab with or without stenting for acute myocardial infarction complicated by cardiogenic shock.
    Giri S; Mitchel J; Azar RR; Kiernan FJ; Fram DB; McKay RG; Mennett R; Clive J; Hirst JA
    Am J Cardiol; 2002 Jan; 89(2):126-31. PubMed ID: 11792329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Gastrointestinal bleeding in a patient with acute myocardial infarction treated with primary coronary angioplasty and abciximab (ReoPro) administration].
    Gziut AI; Pastwa Ł; Słysz A
    Kardiol Pol; 2006 Mar; 64(3):334-6; discussion 337-8. PubMed ID: 16583343
    [No Abstract]   [Full Text] [Related]  

  • 11. Outcomes of optimal or "stent-like"balloon angioplasty in acutemyocardial infarction: the CADILLAC trial.
    Cox DA; Stone GW; Grines CL; Stuckey T; Cohen DJ; Tcheng JE; Garcia E; Guagliumi G; Iwaoka RS; Fahy M; Turco M; Lansky AJ; Griffin JJ; Mehran R;
    J Am Coll Cardiol; 2003 Sep; 42(6):971-7. PubMed ID: 13678914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hemorrhagic and vascular complications after percutaneous coronary intervention with adjunctive abciximab.
    Cote AV; Berger PB; Holmes DR; Scott CG; Bell MR
    Mayo Clin Proc; 2001 Sep; 76(9):890-6. PubMed ID: 11560299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined fibrinolysis using reduced-dose alteplase plus abciximab with immediate rescue angioplasty versus primary angioplasty with adjunct use of abciximab for the treatment of acute myocardial infarction: Asia-Pacific Acute Myocardial Infarction Trial (APAMIT) pilot study.
    Wong A; Mak KH; Chan C; Koh TH; Lau KW; Lim TT; Lim ST; Wong P; Sim LL; Lim YT; Tan HC; Lim YL
    Catheter Cardiovasc Interv; 2004 Aug; 62(4):445-52. PubMed ID: 15274152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gender differences in outcomes after primary angioplasty versus primary stenting with and without abciximab for acute myocardial infarction: results of the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.
    Lansky AJ; Pietras C; Costa RA; Tsuchiya Y; Brodie BR; Cox DA; Aymong ED; Stuckey TD; Garcia E; Tcheng JE; Mehran R; Negoita M; Fahy M; Cristea E; Turco M; Leon MB; Grines CL; Stone GW
    Circulation; 2005 Apr; 111(13):1611-8. PubMed ID: 15811868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.
    Tcheng JE; Kandzari DE; Grines CL; Cox DA; Effron MB; Garcia E; Griffin JJ; Guagliumi G; Stuckey T; Turco M; Fahy M; Lansky AJ; Mehran R; Stone GW;
    Circulation; 2003 Sep; 108(11):1316-23. PubMed ID: 12939213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of drug-eluting and bare-metal stents for primary percutaneous coronary intervention with or without abciximab in ST-segment elevation myocardial infarction: DEBATER: the Eindhoven reperfusion study.
    Wijnbergen I; Helmes H; Tijssen J; Brueren G; Peels K; van Dantzig JM; Van' t Veer M; Koolen JJ; Pijls NH; Michels R
    JACC Cardiovasc Interv; 2012 Mar; 5(3):313-22. PubMed ID: 22440498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bleeding risks with abciximab after full-dose thrombolysis in rescue or urgent angioplasty for acute myocardial infarction.
    Jong P; Cohen EA; Batchelor W; Lazzam C; Kreatsoulas C; Natarajan MK; Strauss BH
    Am Heart J; 2001 Feb; 141(2):218-25. PubMed ID: 11174335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abciximab-associated pseudothrombocytopenia.
    Wool RL; Coleman TA; Hamill RL
    Am J Med; 2002 Dec; 113(8):697-8. PubMed ID: 12505125
    [No Abstract]   [Full Text] [Related]  

  • 19. Coronary artery stenting for suboptimal PTCA results in acute myocardial infarction in patients treated with Abciximab: early and six-month outcome.
    Murdock DK; Logemann T; Hoffmann MT; Olson KJ; Engelmeier RS
    Cathet Cardiovasc Diagn; 1997 Oct; 42(2):173-9. PubMed ID: 9328702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term mortality benefit with the combination of stents and abciximab for cardiogenic shock complicating acute myocardial infarction.
    Chan AW; Chew DP; Bhatt DL; Moliterno DJ; Topol EJ; Ellis SG
    Am J Cardiol; 2002 Jan; 89(2):132-6. PubMed ID: 11792330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.